NCT01915602 - Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 27, 2013

Primary Completion Date

July 29, 2015

Study Completion Date

February 8, 2017

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

Refametinib (BAY86-9766)

Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid

DRUG

Sorafenib (BAY43-9006)

Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.

Trial Locations (79)

704

Tainan City

736

Tainan City

1023

Auckland

1062

Budapest

1070

Bruxelles - Brussel

1090

Vienna

2650

Edegem

3000

Leuven

3010

Bern

4000

Liège

4032

Debrecen

7932

Pécs

8900

Zalaegerszeg

10002

Taipei

10967

Berlin

13005

Marseille

14033

Caen

15706

Santiago de Compostela

20122

Milan

20133

Milan

20246

Hamburg

28007

Madrid

28050

Madrid

33000

Bordeaux

33011

Oviedo

33070

Mersin

34093

Istanbul

34349

Istanbul

34899

Istanbul

36071

Vigo

39120

Magdeburg

40002

Khon Kaen

40138

Bologna

40202

Louisville

42270

Saint-Priest-en-Jarez

45136

Essen

45147

Essen

50200

Chiang Mai

54511

Vandœuvre-lès-Nancy

60596

Frankfurt am Main

64239

Tel Aviv

69004

Lyon

69120

Heidelberg

72076

Tübingen

75012

Paris

90110

Songkhla

100071

Beijing

169610

Singapore

200032

Shanghai

510515

Guangzhou

3109601

Haifa

4941492

Petah Tikva

9112001

Jerusalem

500 05

Hradec Králové

775 20

Olomouc

06202

Nice

Unknown

Hong Kong

00168

Rome

466-8560

Nagoya

260-8677

Chiba

810-8563

Fukuoka

241-8515

Yokohama

589-8511

Osakasayama-shi

350-0495

Irima-gun

113-8655

Bunkyo-ku

173-8610

Itabashi-ku

606-8507

Kyoto

534-0021

Osaka

545-8586

Osaka

08308

Seoul

700-721

Daegu

03722

Seoul

05505

Seoul

06351

Seoul

06591

Seoul

110-744

Seoul

08907

L'Hospitalet de Llobregat

B15 2TH

Birmingham

SE5 9RS

London